Cargando…

In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron

Omicron was designated by the WHO as a VOC on 26 November 2021, only 4 days after its sequence was first submitted. However, the impact of Omicron on current antibodies and vaccines remains unknown and evaluations are still a few weeks away. We analysed the mutations in the Omicron variant against e...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Ye-Fan, Hu, Jing-Chu, Chu, Hin, Yau, Thomas, Zhang, Bao-Zhong, Huang, Jian-Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876352/
https://www.ncbi.nlm.nih.gov/pubmed/35215983
http://dx.doi.org/10.3390/v14020390
_version_ 1784658150272532480
author Hu, Ye-Fan
Hu, Jing-Chu
Chu, Hin
Yau, Thomas
Zhang, Bao-Zhong
Huang, Jian-Dong
author_facet Hu, Ye-Fan
Hu, Jing-Chu
Chu, Hin
Yau, Thomas
Zhang, Bao-Zhong
Huang, Jian-Dong
author_sort Hu, Ye-Fan
collection PubMed
description Omicron was designated by the WHO as a VOC on 26 November 2021, only 4 days after its sequence was first submitted. However, the impact of Omicron on current antibodies and vaccines remains unknown and evaluations are still a few weeks away. We analysed the mutations in the Omicron variant against epitopes. In our database, 132 epitopes of the 120 antibodies are classified into five groups, namely NTD, RBD-1, RBD-2, RBD-3, and RBD-4. The Omicron mutations impact all epitopes in NTD, RBD-1, RBD-2, and RBD-3, with no antibody epitopes spared by these mutations. Only four out of 120 antibodies may confer full resistance to mutations in the Omicron spike, since all antibodies in these three groups contain one or more epitopes that are affected by these mutations. Of all antibodies under EUA, the neutralisation potential of Etesevimab, Bamlanivimab, Casirivimab, Imdevima, Cilgavimab, Tixagevimab, Sotrovimab, and Regdanvimab might be dampened to varying degrees. Our analysis suggests the impact of Omicron on current therapeutic antibodies by the Omicron spike mutations may also apply to current COVID-19 vaccines.
format Online
Article
Text
id pubmed-8876352
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88763522022-02-26 In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron Hu, Ye-Fan Hu, Jing-Chu Chu, Hin Yau, Thomas Zhang, Bao-Zhong Huang, Jian-Dong Viruses Brief Report Omicron was designated by the WHO as a VOC on 26 November 2021, only 4 days after its sequence was first submitted. However, the impact of Omicron on current antibodies and vaccines remains unknown and evaluations are still a few weeks away. We analysed the mutations in the Omicron variant against epitopes. In our database, 132 epitopes of the 120 antibodies are classified into five groups, namely NTD, RBD-1, RBD-2, RBD-3, and RBD-4. The Omicron mutations impact all epitopes in NTD, RBD-1, RBD-2, and RBD-3, with no antibody epitopes spared by these mutations. Only four out of 120 antibodies may confer full resistance to mutations in the Omicron spike, since all antibodies in these three groups contain one or more epitopes that are affected by these mutations. Of all antibodies under EUA, the neutralisation potential of Etesevimab, Bamlanivimab, Casirivimab, Imdevima, Cilgavimab, Tixagevimab, Sotrovimab, and Regdanvimab might be dampened to varying degrees. Our analysis suggests the impact of Omicron on current therapeutic antibodies by the Omicron spike mutations may also apply to current COVID-19 vaccines. MDPI 2022-02-14 /pmc/articles/PMC8876352/ /pubmed/35215983 http://dx.doi.org/10.3390/v14020390 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Hu, Ye-Fan
Hu, Jing-Chu
Chu, Hin
Yau, Thomas
Zhang, Bao-Zhong
Huang, Jian-Dong
In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron
title In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron
title_full In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron
title_fullStr In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron
title_full_unstemmed In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron
title_short In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron
title_sort in-silico analysis of monoclonal antibodies against sars-cov-2 omicron
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876352/
https://www.ncbi.nlm.nih.gov/pubmed/35215983
http://dx.doi.org/10.3390/v14020390
work_keys_str_mv AT huyefan insilicoanalysisofmonoclonalantibodiesagainstsarscov2omicron
AT hujingchu insilicoanalysisofmonoclonalantibodiesagainstsarscov2omicron
AT chuhin insilicoanalysisofmonoclonalantibodiesagainstsarscov2omicron
AT yauthomas insilicoanalysisofmonoclonalantibodiesagainstsarscov2omicron
AT zhangbaozhong insilicoanalysisofmonoclonalantibodiesagainstsarscov2omicron
AT huangjiandong insilicoanalysisofmonoclonalantibodiesagainstsarscov2omicron